|
?:abstract
|
-
A single announcement from the White House prematurely claiming the safety and efficacy of hydroxychloroquine (Plaquenil) as a \'game changer\' for COVID-19 infection was enough to trigger a shortage of this drug 1 Hospitals treating severe COVID-19 cases now face significant challenges in maintaining supplies of far more essential critical care drugs, such as vasopressors, sedatives, and bronchodilators 2 In turn, many states have sought access to Strategic National Stockpile supplies only to find that such life-saving therapies were not available or had not been included in this portfolio 3 With the long bulge of the pandemic curve still to follow, it is likely that other commonly used drugs will face shortages in months to come [ ]most biopreparedness exercises have prepared for an infectious disease threat, such as the anthrax scare, to be a singular and acute event Based on the FDA\'s list, the DEA could provide a responsive review of the production quotas allocated to manufacturers, and the secretary of Health and Human Services could review the need for additional manufacturers to enter the market for certain products, in which case the secretary might consider invoking policies such as Section 1498 6 Under this law, the Secretary can authorize manufacturers to produce an emergency supply ofa drug under patent without the patent holder\'s approval (but providing fair compensation to the patent holder) A recent survey found that hospitals treating many patients with acute COVID-19 in New York City had greater need for life-supporting pharmaceuticals and were therefore at greater risk for shortages than other facilities in New York City or acute care hospitals located in other regions 7 Distributing the existing supply of pharmaceutical products to the neediest facility types and geographic areas may be limited by contractual agreements and FDA regulations
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}